A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across an entire Medicare Advantage contract, beginning with payment-year 2018 audits.
Old Payments Are Suddenly in the Frame
This is still a proposal, not a final rule, and that distinction matters. CMS is taking comments for 60 calendar days after Federal Register publication, with the stated deadline of January 19, 2027. There is room for industry pushback, technical revisions, legal arguments and plain old Washington delay. But investors learned long ago that “not final” is not the same thing as “not material.” Markets price the possibility before the paperwork is dry.
CMS estimates the approach could recover roughly $9 billion per payment year in Medicare Advantage overpayments. That is an agency estimate, not a bill already mailed to insurers, and the notes do not assign a company-by-company liability. Anybody pretending to know the exact hit to each balance sheet right now is selling certainty they do not possess. Still, reaching back to 2018 changes the temperature. Historical exposure is nastier than a prospective rate tweak because reserves, documentation, contract specifics and the eventual audit methodology all become part of the fight.
Why the Selloff Was Not Subtle
Investors reacted with the delicacy of a dropped toolbox. On November 18, UnitedHealth fell 10.21% to $349.91, Humana dropped 12.98% to $385.78 and CVS Health slipped 5.2% to $81.35; UnitedHealth continued lower in Thursday trading. That kind of move says the market is worrying about more than one quarter. It is staring at the durability of Medicare Advantage economics and asking whether risk-adjustment revenue that once looked settled may be subject to a broader clawback framework.
NYSE:UNH brings enormous scale to the conversation. Its third-quarter 2026 revenue was $112.7 billion and operating earnings were $6.6 billion, alongside a medical cost ratio of 88.4%. It also raised its full-year adjusted earnings outlook to at least $20.50 per share. Those are substantial current operating numbers. Yet scale cuts both ways in a regulatory storm: a big platform can absorb shocks, but it also gives any change in audit treatment a much larger surface area.
Strong Quarterly Prints Do Not Erase Policy Risk
NYSE:CVS reported third-quarter revenue of $108.4 billion, up 5.4% year over year, and raised 2026 adjusted EPS guidance to at least $8.20. It also lifted operating cash-flow guidance to at least $15.5 billion. That is real evidence of operating momentum, not fluff. The catch is that investors have to separate present execution from a rule proposal that may affect future recoveries and past payments. Both can be true at once, which is precisely why these stocks can feel impossible on a day like this.
Elevance posted $50.4 billion in third-quarter operating revenue and raised full-year adjusted EPS guidance to at least $29.00, while Molina reaffirmed approximately $42 billion in 2026 premium revenue and adjusted earnings of at least $5.25 per share. Those updates show these companies are not standing still, helpless in the rain. But no management guidance in the supplied figures answers the key RADV questions: how broadly CMS will extrapolate, how disputes will be adjudicated, and what the final timing looks like.
The Details Investors Cannot Skip
- Watch the final rule's audit methodology, especially how sampled findings are projected across a contract.
- Watch whether the 2018 starting point survives comments and any later challenge.
- Watch company disclosures for reserves, contingencies and any quantified estimate of exposure.
- Watch Medicare Advantage margins separately from headline revenue growth.
Humana's December 1 national Gold Card program, which waives prior authorization for eligible providers on certain imaging and therapy services, is a reminder that insurers are still managing care delivery while this regulatory cloud forms. Its earlier pilot included about 400 providers representing more than 8,000 clinicians. Useful operational news, sure, but it does not answer the audit-recovery question.
The sober read is not that every managed-care name is broken. It is that investors have been handed a fat, unresolved variable with potentially backward-looking consequences. Until CMS turns proposal into final language, the smart posture is vigilance rather than bravado. The numbers on these businesses remain large; the uncertainty surrounding them just got larger too.